Details of the Drug

General Information of Drug (ID: DMOSRFZ)

Drug Name
OC-10X
Synonyms AMD therapy, OcuCure
Indication
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 1 [1]
Proliferative diabetic retinopathy 9B71.01 Phase 1 [2]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 300.4
Logarithm of the Partition Coefficient (xlogp) 4.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C20H16N2O
IUPAC Name
2-(4-phenylphenyl)-2,3-dihydro-1H-quinazolin-4-one
Canonical SMILES
C1=CC=C(C=C1)C2=CC=C(C=C2)C3NC4=CC=CC=C4C(=O)N3
InChI
InChI=1S/C20H16N2O/c23-20-17-8-4-5-9-18(17)21-19(22-20)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,19,21H,(H,22,23)
InChIKey
XRUAOBKXCFNPCK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4793207
TTD ID
D00YBZ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin receptor (TUBR) TT9K83W NOUNIPROTAC Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023889)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01869933) Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X. U.S. National Institutes of Health.